/Doctor%20using%20microscope%20in%20medical%20research%20lab%20for%20vaccine%20development%20by%20Yingyaipumi%20via%20Adobe%20Stock.jpeg)
Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $17.6 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Tuesday, Nov. 3.
Ahead of the event, analysts expect Revvity to report a profit of $1.28 per share on a diluted basis, up 8.5% from $1.18 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
